Literature DB >> 9534213

New World cutaneous leishmaniasis imported into Australia.

G P Maguire1, I Bastian, S Arianayagam, A Bryceson, B J Currie.   

Abstract

A case of cutaneous leishmaniasis in a traveller from Belize, Central America is reported. Leishmaniasis presents rarely in Australia and delays in diagnosis and treatment often occur. A high index of suspicion in a patient who has returned from an endemic region is required. Subsequent confirmation of a diagnosis of cutaneous leishmaniasis is best achieved by demonstration of the organism on skin biopsy, aspiration or smear. The histology is variable and depends on geographic, parasite species and host factors. Speciation of New World disease as either Leishmania braziliensis or Leishmania mexicana is important to determine the risk of later development of mucosal disease, which normally only occurs with L. braziliensis infection, and for optimal treatment. Several different modes of treatment have been suggested, but antimonials, such as sodium stibogluconate, remain the treatment of choice in New World cutaneous leishmaniasis.

Entities:  

Mesh:

Year:  1998        PMID: 9534213     DOI: 10.1080/00313029800169715

Source DB:  PubMed          Journal:  Pathology        ISSN: 0031-3025            Impact factor:   5.306


  3 in total

1.  Post-kala-azar dermal leishmaniasis due to Leishmania infantum in a human immunodeficiency virus type 1-infected patient.

Authors:  D Stark; S Pett; D Marriott; J Harkness
Journal:  J Clin Microbiol       Date:  2006-03       Impact factor: 5.948

2.  Molecular epidemiology of imported cases of leishmaniasis in Australia from 2008 to 2014.

Authors:  Tamalee Roberts; Joel Barratt; Indy Sandaradura; Rogan Lee; John Harkness; Deborah Marriott; John Ellis; Damien Stark
Journal:  PLoS One       Date:  2015-03-03       Impact factor: 3.240

3.  A case of imported Leishmania infantum cutaneous leishmaniasis; an unusual presentation occurring 19 years after travel.

Authors:  Amy Crowe; John Slavin; Damien Stark; Craig Aboltins
Journal:  BMC Infect Dis       Date:  2014-11-27       Impact factor: 3.090

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.